Sponsor pipeline

Transcenta Therapeutics (Hangzhou) Co., Ltd. clinical trial pipeline

Get alerts when Transcenta Therapeutics (Hangzhou) Co., Ltd.'s trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-10-16

What changed in the last 30 days

4 trials changed in the last 30 days: 0 stopped, 4 with notable changes, 0 with minor changes only.

  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.

Active trials by phase

Phase 1/2
3
Phase 2
1
Phase 3
1

Active trials

NCT IDTitleConditionStatusUpdated
Phase 3
NCT06093425 Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy… Gastric Cancer Not Yet Recruiting 2026-09-29
Phase 2
NCT07806331 Study of TST002 Injection in Postmenopausal Women With Osteoporosis or Low Bone Mass Postmenopausal Osteoporosis Not Yet Recruiting 2026-09-11
Phase 1/2
NCT04396821 A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid… Advanced Cancer Active, Not Recruiting 2026-09-29
NCT04495296 A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of… Advanced Cancer Active, Not Recruiting 2026-09-29
NCT05731271 A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors Locally Advanced Solid Tumor Active, Not Recruiting 2026-09-29

Disease areas by active trials

Gastric Cancer (2) · Colorectal Cancer (1) · Pancreatic Cancer (1)

Get alerts when Transcenta Therapeutics (Hangzhou) Co., Ltd.'s trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free